Skip to main content

Melanoma and Other Tumors of the Skin

  • Chapter
Current Cancer Therapeutics
  • 129 Accesses

Abstract

The most commonly occurring human neoplasms are those arising in the skin. The nonmelanoma neoplasms are chiefly squamous and basal cell carcinomas that evolve slowly, generally permitting early recognition and cure by local. Less often, radiation and topical chemotherapeutic approaches are used. Melanoma is a less common but more aggressive cutaneous neoplasm that in up to 15% of patients, has a considerably more lethal progression pattern, involving regional and distant sites. Recently, new biologic therapies capable of preventing relapse after surgical excision and leading to sustained regression in patients with metastatic disease have been identified. Melanoma less frequently arises in a variety of noncutaneous sites, including the mucosae and subungual areas of the toes and fingers and the uveal tract of the eye. Indeed ocular melanoma is the most lethal tumor of the eye in adults. The incidence of melanoma has risen more rapidly than any other solid tumor. Approximately 45,000 patients develop melanoma annually, with one in 75 white patients expected to be at risk for developing melanoma in their lifetime at the beginning of this millennium [1]. Interestingly, the increase appears to be primarily in thin melanomas, those most readily cured with simple excision [2]. The following chapter will deal solely with cutaneous melanoma and basal and squamous cell carcinomas, the predominant skin cancers that confront the clinician.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 39.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 54.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Lotze MT, Dallai RM, Kirkwood JM, Flickinger JC: Cutaneous melanoma. In Principles and Practice of Oncology. Edited by DeVita V, Hellman S, Rosenberg S. Philadelphia: Lippincott-Raven; 2000

    Google Scholar 

  2. Lipsker DM, Hedelin G, Heid E,et al.: Striking increase of thin melanomas contrasts with stable incidence of thick melanomas.Arch Dermato1 1999, 135: 1451–1456

    Article  CAS  Google Scholar 

  3. Skolnick, MH, Cannon-Albright LA, Kamb A: Genetic predisposition to melanoma. EurJCancer 1994, 30A: 1991–1995

    Article  Google Scholar 

  4. Whelan AJ, Bartsch D, Goodfellow PJ: A familial syndrome of pancreatic cancer and melanoma with a mutation in the CDKN2 tumor-suppressor gene. N Eng1 JMed 1995, 333: 970–974

    Article  Google Scholar 

  5. Goldstein AM, Struewing JP, Chidambaram A, Fraser MC, Tucker MA: Genotype-phenotype relationships in U.S. melanoma-prone families with CDKN2A and CDK4 mutations. J Nat/ Cancer Inst 2000, 92: 1006–1010

    Article  CAS  Google Scholar 

  6. Wang Y, Rao U, Mascari R, Richards TJ, et al.: Molecular analysis of melanoma precursor lesions. Cell Growth Differ 1996, 7: 1733–1740

    PubMed  CAS  Google Scholar 

  7. Titus-Ernstoff L, Duray PH, Ernstoff MS, et al.: Dysplastic nevi in association with multiple primary melanoma. Cancer Res 1998, 48: 1016–1018

    Google Scholar 

  8. Ziegler A, Jonason AS, Leffel DJ, et al.: Sunburn and p53 in the onset of skin cancer. Nature 1994, 372: 773–776

    Article  PubMed  CAS  Google Scholar 

  9. Rhodes AR: Public education and cancer of the skin. Cancer 1995, 75: 613–636

    Article  PubMed  CAS  Google Scholar 

  10. Wang C, Brodland DG, Su WPD: Skin cancers associated with acquired immunodeficiency syndrome [abstract].Mayo Clin Proc 1995, 70: 766–772

    Article  PubMed  CAS  Google Scholar 

  11. Cheson BD, Vena DA, Barrett J, Freidlin B: Second malignancies as a consequence of nucleoside analog therapy for chronic lymphoid leukemias. J Clin Oncol 1999, 17: 2454–2460

    PubMed  CAS  Google Scholar 

  12. Maeurer MJ, Lotze MT: Immune responses to melanoma antigens. In Cutaneous Melanoma, edn 3. Edited by Balch CM, Houghton AN, Sober AJ, Soong S-J. St. Louis: Quality Medical Publishing, Inc.; 1998: 517–534

    Google Scholar 

  13. Balch CM: A new AJCC staging system for cutaneous melanoma.Cancer 2000

    Google Scholar 

  14. Poo-Hwu WJ, Ariyan S, Lamb L, et al.: Follow-up recommendations for patients with American Joint Committee on Cancer Stages I-III malignant melanoma. Cancer 1999, 86: 2252–2258

    Article  PubMed  CAS  Google Scholar 

  15. Essner R, Bostick PJ, Glass EC, et al.: Standardized probe-directed sentinel node dissection in melanoma. Surgery 2000, 127: 26–31

    Article  PubMed  CAS  Google Scholar 

  16. Balch CM, Sengjaw S, Ross M, et al.: Long-term results of a multiinstitutional randomized trial: Comparing prognostic factors and surgical results for intermediate thickness melanoma (1.0–4.0 mm). Ann Surg Oncol 2000, 7: 87–97

    Article  PubMed  CAS  Google Scholar 

  17. Karakousis CP, Velez A, Driscoll DL, Takita H: Metastasectomy in malignant melanoma. Surgery 1994, 115: 295–302

    PubMed  CAS  Google Scholar 

  18. Manola J, Atkins M, Ibrahim J, Kirkwood J: Prognostic factors in metastatic melanoma: a pooled analysis of Eastern Cooperative Oncology Group trials. J Clin Oncol 2000, 18: 3782–3793

    PubMed  CAS  Google Scholar 

  19. Kondziolka D, Patel A, Lunsford LD, et al.: Stereotactic radiosurgery plus whole brain radiotherapy versus radiotherapy alone for patients with multiple brain metastases. IntJRadiat Oncol Biol Phys 1999, 45: 427–434

    Article  CAS  Google Scholar 

  20. Falkson CI, Falkson G, Falkson HC: Improved results with the addition of interferon alfa-2b to dacarbazine in the treatment of patients with metastatic malignant melanoma. J Clin Oncol 1991, 9: 1403–1408

    PubMed  CAS  Google Scholar 

  21. Middleton MR, Grob JJ, Aaronson N, et al.: Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma. J Clin Oncol 2000, 18: 158

    PubMed  CAS  Google Scholar 

  22. Rustoven JJ, Quirt IC, Iscoe NA, et al.: Randomized, double-blind, placebo-controlled trial comparing the response rates of carmustine, dacarbazine, and cisplatin with and without tamoxifen in patients with metastatic melanoma. J Clin Oncol 1996, 14: 2083–2090

    Google Scholar 

  23. Fallcson CI, Ibrahim J, Kirkwood JM, et al.: Phase III trial of dacarbazine versus dacarbazine with interferon alfa-2b versus dacarbazine with tamoxifen versus dacarbazine with interferon alfa-2b and tamoxifen in patients with metastatic malignant melanoma: an Eastern Cooperative Oncology Group Study (E3690). J Clin Oncol 1998, 16: 1743–1751

    Google Scholar 

  24. Del Prete SA, Maurer LH, O’Donnell J, et al.: Combination chemotherapy with cisplatin, carmustine, dacarbazine and tamoxifen in malignant melanoma. Cancer Treat Rep 1984, 68: 1403–1405

    PubMed  Google Scholar 

  25. Chapman PB, Einhorn LH, Meyers ML, et al.: Phase III multicenter randomized trial of the Dartmouth regimen versus dacarbazine in patients with metastatic melanoma. J Clin Oncol 1999, 17: 2745–2751

    PubMed  CAS  Google Scholar 

  26. Kirkwood JM: Biologic therapy with interferon a and b: clinical applications: melanoma. In Biologic Therapy of Cancer: Principles and Practice. Edited by DeVita VT, Jr., Hellman S, Rosenberg SA. Philadelphia: JB Lippincott; 1995: 388–411

    Google Scholar 

  27. Lotze MT: The future role of interleukin-2 in cancer therapy. CancerJ Sci Am 2000, 6 (suppl 1): S58 – S60

    PubMed  Google Scholar 

  28. Royal RE, Steinberg SM, Krouse RS, et al.: Correlates of response to IL-2 therapy in patients treated for metastatic renal cancer and melanoma. Sci Am 1996, 2: 91–98

    CAS  Google Scholar 

  29. Keilholz U, Scheibenbogen C, Tilgen W, et al.: Interferon-a and interleukin-2 in the treatment of metastatic melanoma: comparison of two phase II trials. Cancer 1993, 72: 607–614

    Article  PubMed  CAS  Google Scholar 

  30. Atkins MB, Lotze MT, Dutcher JP, et al.: High-dose recombinant interleukin-2 therapy for patients with metastatic melanoma: analysis of 270 patients treated from 1985–1993. J Clin Oncol 1999, 17: 2105

    Google Scholar 

  31. Hoon DS, Yuzuki D, Hayashida M, et al.: Melanoma patients immunized with melanoma cell vaccine induce antibody responses to recombinant MAGE-1 antigen. J lmmunol 1995, 154: 730–737

    Google Scholar 

  32. Lotze MT, Shurin M, Esche C, et al.: Interleukin-2: developing additional cytokine gene therapies using fibroblasts or dendritic cells to enhance tumor immunity. Cancer J Sci Am 2000, 6 (suppl 1): S61 - S66

    PubMed  Google Scholar 

  33. Lienard D, Ewalenko P, Delmotte JJ, et al.: High-dose recombinant tumor necrosis factor alpha in combination with interferon gamma and melphalan in isolation perfusion of the limbs for melanoma and sarcoma. J Clin Oncol 1992, 10: 52–60

    PubMed  CAS  Google Scholar 

  34. Lienard D, Eggermont AM, Koops HS, et al.: Isolated limb perfusion with tumor necrosis factor-alpha and melphalan with or without interferon-gamma for the treatment of in-transit melanoma metastases: a multicenter randomized phase II study. Melanoma Res 1999, 9: 491–502

    Article  PubMed  CAS  Google Scholar 

  35. Barth A, Wanke LA, Morton DL: Analysis of prognostic factors in 1521 patients with metastatic melanoma [abstract]. Proc ASCO 1995, 14: 410

    Google Scholar 

  36. Flaherty LE, Robinson W, Redman BG, et al.: A phase II study of dacarbazine and cisplatin in combination with outpatient administered interleukin-2 in metastatic malignant melanoma. Cancer 1993, 71: 3520–3525

    Article  PubMed  CAS  Google Scholar 

  37. Sirott MN, Bajorin DF, Wong GY, et al.: Prognostic factors in patients with metastatic malignant melanoma: a multivariate analysis. Cancer 1993, 72: 3091–3098

    Article  PubMed  CAS  Google Scholar 

  38. Kirkwood JM, Wilson J, Whiteside TL, et al.: Phase IB trial of picibanil (OK-432) as an immunomodulator in patients with resected high-risk melanoma. Cancer Immunol Immunother 1997, 44: 137–149

    Article  PubMed  CAS  Google Scholar 

  39. Lear JT, Strange RC, Fryer AA: Relationship between sunlight exposure and a key genetic alteration in basal cell carcinoma. JNatl Cancer Inst 1997, 89: 454–455

    Article  PubMed  CAS  Google Scholar 

  40. Spitler LE: A randomized trial of levamisole versus placebo as adjuvant therapy in malignant melanoma. J Clin Oncol 1991, 9: 736–740

    PubMed  CAS  Google Scholar 

  41. Kirkwood, JM, Strawderman MH, Ernstoff MS, et al.: Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST1684. J Clin Oncol 1996, 14: 7–17

    PubMed  CAS  Google Scholar 

  42. Cole BF, Gelber RD, Kirkwood JM, et al.: A quality-of-life-adjusted survival analysis of interferon alfa-2b adjuvant treatment for high-risk resected cutaneous melanoma: an Eastern Cooperative Oncology Group Study (E1684). J Clin Onco1 1996, 14: 2666–2673

    Google Scholar 

  43. Hillner BE, Kirkwood JM, Atkins MB, et al.: Economic analysis of adjuvant interferon alfa-2b in high-risk melanoma based on projections from ECOG 1684. J Clin Onco1 1997, 15: 2351–2358

    Google Scholar 

  44. Kirkwood JM, Ibrahim JG, Sondak VK, et al.: High- and low-dose interferon alfa-2b in high-risk melanoma: first analysis of intergroup trial E1690/S9111/C9190. J Clin Oncol 2000, 18: 2444–2458

    PubMed  CAS  Google Scholar 

  45. Strom EA, Ross MI: Adjuvant radiation therapy after axillary lymphadenectomy for metastatic melanoma: toxicity and local control. Ann Surg Onco1 1995, 2: 445–449

    Article  CAS  Google Scholar 

  46. Wallack MK, Sivanandham M, Balch CM, et al.: A phase III randomized, double-blind, multiinstitutional trial of vaccine melanoma oncolysate-active specific immunotherapy for patients with stage II melanoma. Cancer 1995, 75: 34–42

    Article  PubMed  CAS  Google Scholar 

  47. Mayordomo JI, Zorina T, Storkus WJ, et al.: Bone marrow-derived dendritic cells pulsed with synthetic tumor peptides elicit protective and therapeutic antitumor immunity.Nature Medicine 1995, 1: 1297–1302

    Article  PubMed  CAS  Google Scholar 

  48. Zitvogel L, Mayordomo JI, Tjandrawan T, et al.: Therapy of murine tumors with tumor peptide-pulsed dendritic cells: dependence on T cells, B7 costimulation, and T helper cell 1-associated cytokines. JExp Med 1996, 183: 87–97

    Article  PubMed  CAS  Google Scholar 

  49. Luft T, Pang KC, Thomas E, et al.: Type I IFNs enhance the terminal differentiation of dendritic cells.Jlmmunol 1998, 161: 1944–1953

    Google Scholar 

  50. Nestle FO, Alijagic S, Gilliet M, et al.: Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nature Medicine 1998, 4: 328–332

    Article  PubMed  CAS  Google Scholar 

  51. Favilla I, Favilla ML, Gosbell AD, et al.: Photodynamic therapy: a 5-year study of its effectiveness in the treatment of posterior uveal melanoma, and evaluation of haematoporphyrin uptake and photocytotoxicity of melanoma cells in tissue culture. Melanoma Res 1995, 5: 355–364

    Article  PubMed  CAS  Google Scholar 

  52. Coupland SE, Anastassiou G, Stang A, et al.: The prognostic value of cyclin D1, p53, and MDM2 protein expression in uveal melanoma. J Pathol 2000, 91: 120–126

    Article  Google Scholar 

  53. Alexander HR, Libutti SK, Bartlett DL, et al.: A phase I-II study of isolated hepatic perfusion using melphalan with or without tumor necrosis factor for patients with ocular melanoma metastatic to liver. Clin Cancer Res 2000, 6: 3062–70

    PubMed  CAS  Google Scholar 

  54. Preston DS, Stern RS: Nonmelanoma cancers of the skin. NEng1J Med 1992, 327: 1649–1662

    Article  CAS  Google Scholar 

  55. Cullen SI: Topical fluorouracil therapy for precancer and cancers of the skin. J Am Geriatr Soc 1997, 27: 529–535

    Google Scholar 

  56. Ashton H, Beveridge GW, Stevenson CJ: Topical treatment of skin tumors with 5-flourouracil. BrJDermato1 1970, 82: 207–209

    Google Scholar 

  57. Soufir N, Daya-Grosjean L, de La Salmoniere P et al.: Association between INK4a-ARF and p53 mutation in skin carcinomas of xeroderma pigmentosum patients. J Natl Cancer Inst 2000, 92: 1841–1847

    Article  CAS  Google Scholar 

  58. Miller SJ: The National Comprehensive Cancer Network (NCCN) guidelines of care for nonmelanoma skin cancers. Dermatol Surg 2000 26: 289–292

    Article  PubMed  CAS  Google Scholar 

  59. Kirkwood J, Ibrahim J, Lawson D, et al.: E2696: a trial of vaccination with or without IFNα2b in high-risk resected melanoma. J Clin Oncol 2001, in press

    Google Scholar 

Download references

Authors

Rights and permissions

Reprints and permissions

Copyright information

© 2001 Springer Science+Business Media New York

About this chapter

Cite this chapter

Lotze, M.T., Kirkwood, J.M. (2001). Melanoma and Other Tumors of the Skin. In: Current Cancer Therapeutics. Current Medicine Group, London. https://doi.org/10.1007/978-1-4613-1099-0_11

Download citation

  • DOI: https://doi.org/10.1007/978-1-4613-1099-0_11

  • Publisher Name: Current Medicine Group, London

  • Print ISBN: 978-1-57340-176-0

  • Online ISBN: 978-1-4613-1099-0

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics